Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neighbourly Pharmacy Inc T.NBLY

Neighbourly Pharmacy Inc. is a Canada-based company that operates a network of community pharmacies. The Company is an owner and operator of retail pharmacies located throughout Canada under banners such as IDA/Guardian, Pharmachoice, Pharmasave and Remedy’s RX. The Company, through its subsidiaries, owns and operates a network of retail pharmacies known as Rubicon Pharmacies (Rubicon or Rubicon Pharmacies. The Company owns and operates approximately 287 locations across seven provinces and one territory, a coast-to-coast footprint that provides scale and diversification. The Company’s pharmacies provide accessible healthcare with a personal touch. The Company also owns British Columbia-based pharmacies.


TSX:NBLY - Post by User

Post by retiredcfon Jul 06, 2023 6:33am
171 Views
Post# 35528620

Stockchase Insights

Stockchase Insights
HOLD
Neighbourly Pharmacy Inc(NBLY-T)
05/07/2023
 
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research
NBLY has not been a public company for very long (IPO'd in mid-2021), but its growth rates are strong, and while it is not yet profitable, it is on the cusp of becoming profitable. Its forward P/E is now fairly high at 31.3X, but its price to book is 1.2X and its forward sales multiple is cheap at 0.8X. It has a ~5.7% free cash flow yield and its balance sheet is strong. With a net profit margin of ~(2%), if sales growth continues at a fast pace and it becomes profitable, we believe that its strong fundamental base can begin to be appreciated by investors. We do not like the negative momentum recently, but we believe it has a lot to offer and it is now nearing its book value. In a rising interest rate environment, unprofitable names are still not investors' number one preference, but we expect NBLY's high growth rates to be a tailwind over the long-term. 
 
Healthcare
 
$15.880
Unknown
<< Previous
Bullboard Posts
Next >>